Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy
Home stool DNA tests done every three years catch more precancerous growths and prevent more colorectal cancers than colonoscopy alone, helping more people get screened.
Using a validated microsimulation model calibrated to real-world adherence rates, triennial next-generation stool DNA testing outperformed single decennial colonoscopy across all 10-year outcomes: 13% more precancerous lesions detected, 33% vs 20% CRC mortality reduction, and 62% more life-years gained. These findings support expanded use of noninvasive stool-based CRC screening to address colonoscopy capacity constraints and improve population-level participation.
What the study was
- Study design
- Microsimulation modeling study (validated CRC-AIM model)
- Population
- General US population eligible for CRC screening, n=1,000 per 1,000-person model cohort
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Journal of Medical Economics
Why it surfaced
High public health relevance for population-level CRC prevention; addresses adherence-gap problem in colonoscopy programs; modeling study limits design quality score. COI note: several authors affiliated with Exact Sciences (Cologuard manufacturer).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.